FDA official logo
GSRS logo
PFDA official logo

NIRSEVIMAB

  • UNII: VRN8S9CW5V
  • Preferred Substance Name: NIRSEVIMAB

  • 1989556-22-0
  • BEYFORTUS
  • IMMUNOGLOBULIN G1, ANTI-(HUMAN RESPIRATORY SYNCYTIAL VIRUS FUSION PROTEIN)(HUMAN MONOCLONAL MED18897 .GAMMA.1-CHAIN), DISULFIDE WITH MONOCLONAL MED18897 .KAPPA.-CHAIN, DIMER
  • IMMUNOGLOBULIN G1-KAPPA, ANTI-(HUMAN RESPIRATORY SYNCYTIAL VIRUS FUSION GLYCOPROTEIN F0 (PROTEIN F))HUMAN MONOCLONAL ANTIBODY.GAMMA.1 HEAVY CHAIN (1-456) (HUMAN VH (HOMO SAPIENS IGHV1-69*01(IGHD)-IGHJ4*01 (90.1%)) (8.8.19) (1-126) -HOMO SAPIENS IGHG1*03 (CH2 M22>Y(261),S24>T(263),T26>E(265)) (127-456)) (229-214')-DISULFIDE WITH KAPPA LIGHT CHAIN (1'-214') (HUMAN V-KAPPA (HOMO SAPIENS IGKV1-33*01IGKJ4*01)(96%) (6.3.9) (1'-107') -HOMO SAPIENS IGKC*01 (108'-214')), DIMER (235-235'':238-238'')-BISDISULFIDE
  • MED-18897
  • MEDI8897
  • NIRSEVIMAB [INN]
  • NIRSEVIMAB [JAN]
  • NIRSEVIMAB [USAN]
  • NIRSEVIMAB [WHO-DD]

Note

UNIIs are generated based on scientific identity characteristics using ISO 11238 data elements. UNII availability does not imply any regulatory review or approval. Synonyms and mappings are based on the best public information available at the time of publication. Please report any problems/errors associated with this data to FDA-SRS@fda.hhs.gov.